95 results
Page 3 of 5
6-K
EX-99.1
edk83l
18 Jan 22
SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110
4:27pm
6-K
EX-99.1
sc7s1
6 Jan 22
SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer’s Disease
9:09am
6-K
EX-99.1
w6buefkq
29 Dec 21
SciSparc Provides Updates Upon Conclusion of 2021
5:12pm
6-K
EX-99.2
ulgoitohnyimeiaqxod
16 Aug 21
Interim Consolidated Financial Statements
12:00am
6-K
EX-99.1
5uj02a 4d
4 Aug 21
SciSparc Announces Completion of Corporate Rebranding and Launch of New Website
4:44pm
6-K
EX-99.1
o50udu2fobyr06
28 Jul 21
SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome
4:00pm
6-K
EX-99.1
lco1znq3ym 0eo1pth3
7 Jul 21
Current Report of Private Issuer
4:00pm
6-K
EX-99.2
q7hlgaem2r5i
2 Mar 21
Report of Foreign Private Issuer
4:05pm
6-K
EX-99.1
zqr1g9r
24 Feb 21
SciSparc Corporate Presentation February 2021
9:27am
6-K
EX-99.1
inqkf4 pn
17 Feb 21
Report of Foreign Private Issuer
8:35am
6-K
EX-99.1
z3xbd
10 Feb 21
SciSparc Engages Procaps for Development and Production of CannAmide™ and its SCI-110 Product Candidate
8:33am
6-K
EX-99.1
tk2wz516
5 Jan 21
Therapix Biosciences and Cyntar Ventures Entered a Non-Binding Letter of Intent for the Distribution of TheraPEA in Canada
9:12am
424B4
yv1c02w9 26gtbxjw3e
20 Nov 20
Prospectus supplement with pricing info
4:43pm
FWP
tjmsh3e4k8f9u7
5 Nov 20
Free writing prospectus
5:11pm
F-1/A
099xy6nhe68 68
4 Nov 20
Registration statement (foreign) (amended)
2:14pm
F-1/A
EX-4.6
d5lwadxwlo88eg6
4 Nov 20
Registration statement (foreign) (amended)
2:14pm
FWP
chnx0elibpc4 z6
21 Oct 20
Free writing prospectus
7:26am
F-1/A
09qs2uebdxzc1a
20 Oct 20
Registration statement (foreign) (amended)
9:57pm
F-1/A
EX-1.1
nagpfq w706m
9 Oct 20
Registration statement (foreign) (amended)
12:00am